Core Viewpoint - *ST Shuangcheng (002693.SZ) has recently received marketing authorization for its arginine vasopressin injection from the Australian Therapeutic Goods Administration (TGA) [1] Group 1: Company Developments - The company has obtained a significant regulatory approval for its arginine vasopressin injection, which is a critical step for market entry [1] - The product is available in a specification of 20 pressor units per 1 mL [1] Group 2: Market Insights - According to the Insight database, the global sales for arginine vasopressin injection are projected to reach approximately $72 million in 2024 [1] - The U.S. market is expected to contribute around $46 million to the total sales [1]

一、药品基本情况 1、药品商品名：精氨加压素注射液 2、剂型：注射剂 3、规格：20 pressor units/1 mL 4、获批适应症：适用于预防和治疗术后腹胀；清除腹部 X 射线检查中的干 扰性气体阴影；以及用于治疗尿崩症。 上市许可的公告 证券代码：002693 证券简称：*ST双成 公告编号：2025-051 海南双成药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 关于精氨加压素注射液获得澳大利亚药物管理局（TGA） 海南双成药业股份有限公司（以下简称"公司"） 于近日收到澳大利亚药 物管理局（TGA）签发的精氨加压素注射液的上市许可，现将相关情况公告如下： 根据 Insight 数据库查询到的销售信息显示，精氨加压素注射液（20 pressor units/1 mL 规格）2024 年全球销售总额约 7,200 万美元，其中美国市场销售额 约为 4,600 万美元。 三、对公司的影响及风险提示 本次精氨加压素注射液获得澳大利亚药物管理局签发的上市许可，表明公司 精氨加压素注射液具备了在澳大利亚进行销售的资质。对公司拓展海外市场、提 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： 1、本次股东会没有出现否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议。 一、会议召开和出席情况 1、现场会议召开时间：2025年7月31日（星期四）下午14：30 网络投票时间：2025年7月31日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年7月31日9:15-9:25，9:30-11:30 和13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年7月31日9:15-15:00期间的任意时间。 2、会议召开地点：海南省海口市秀英区兴国路16号公司会议室 3、会议召开方式：现场投票结合网络投票方式 4、会议召集人：公司董事会 现场出席会议的股东海南双成投资有限公司、HSP Investment Holdings Limited及王成栋先生为关联股 东，合计持有公司股份203,226,831股。关联股东在审议本议案时回避表决。 5、会议主持人：董事长王成栋 6、本次股东会会议的召集、召开 ...

据证券之星公开数据整理，近期*ST双成（002693）发布2025年中报。根据财报显示，*ST双成净利润 减8.97%。截至本报告期末，公司营业总收入8412.21万元，同比下降11.35%，归母净利润-1846.66万 元，同比下降8.97%。按单季度数据看，第二季度营业总收入4744.63万元，同比下降8.99%，第二季度 归母净利润-842.61万元，同比下降2.71%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率46.72%，同比减24.34%，净利 率-27.38%，同比减7.28%，销售费用、管理费用、财务费用总计5918.06万元，三费占营收比70.35%， 同比减10.3%，每股净资产0.9元，同比减17.13%，每股经营性现金流-0.0元，同比增93.2%，每股收 益-0.04元，同比减8.8% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 9489.26万 | 8412.21万 | -11.35% | | 归母净利润(元) | -1694.62万 | -1846.66万 | -8 ...

北京市中伦律师事务所 关于海南双成药业股份有限公司 2025 年第一次临时股东会的 法律意见书 二〇二五年七月 北京市中伦律师事务所 关于海南双成药业股份有限公司 2025 年第一次临时股东会的 法律意见书 致：海南双成药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受海南双成药业股份有限公 司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》《上市公司股东会规则》（以下简称《股东会 规则》）等法律、法规、规范性文件及《海南双成药业股份有限公司章程》（以下 简称《公司章程》）的有关规定，就公司 2025 年第一次临时股东会（以下简称"本 次股东会"）有关事宜出具本法律意见书。 本法律意见书仅就本次股东会的召集人资格、召集和召开程序、出席本次股 东会人员的资格（但不包含网络投票股东的资格）、会议表决程序是否符合法律、 法规、规范性文件及《公司章程》的规定以及表决结果是否合法有效发表意见， 而不对本次股东会所审议的议案内容以及该等议案所表述的相关事实或数据的 真实性、准确性或合法性发表意见。 本法律意见书仅供本次股东会之目的而使用，未经本所书面同 ...

证券代码：002693 证券简称：*ST双成 公告编号：2025-050 海南双成药业股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会没有出现否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议。 一、会议召开和出席情况 1、现场会议召开时间：2025年7月31日（星期四）下午14：30 网络投票时间：2025年7月31日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年7 月31日9:15-9:25，9:30-11:30和13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年7月31日 9:15-15:00期间的任意时间。 6、本次股东会会议的召集、召开和表决程序符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第1号——主板上市公司规范运作》和《海南双成药业股份 有限公司章程》等规定。 7、出席会议的股东（含网络投票）共596人，代表股份213,952, ...

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. (referred to as "Shuangcheng Pharmaceutical") reported a significant decline in revenue and an expanded net loss for the first half of 2025, raising concerns about its potential delisting if it fails to turn around its financial performance by the end of the year [1][5]. Financial Performance - For the first half of 2025, Shuangcheng Pharmaceutical achieved operating revenue of 84.12 million yuan, a year-on-year decrease of 11.35% [1]. - The net loss attributable to shareholders was 18.47 million yuan, worsening from previous losses [1]. - Revenue has been consistently declining over the past three years, with figures of 275 million yuan, 236 million yuan, and 174 million yuan for 2022, 2023, and 2024 respectively, reflecting year-on-year declines of 14.22%, 14.18%, and 26.16% [3]. Industry Challenges - The pharmaceutical industry is facing increased scrutiny and regulatory measures, impacting Shuangcheng Pharmaceutical's operations in the peptide market [2]. - Rising costs of raw materials due to stricter environmental regulations have further pressured the company's production costs [2]. Strategic Moves - Shuangcheng Pharmaceutical attempted a strategic shift by planning a major asset restructuring to acquire shares in Ningbo Aura Semiconductor Co., Ltd. (referred to as "Aura"), aiming to transition into the semiconductor industry [6][7]. - The stock price surged significantly following the announcement of this acquisition, reaching a peak of 40.98 yuan per share, a cumulative increase of 685% [7]. Failed Transformation - The acquisition of Aura was ultimately terminated due to disagreements on transaction terms and expectations among the parties involved [8]. - The failure of this transformation effort has compounded the company's operational challenges and financial instability [11]. Current Strategies - Shuangcheng Pharmaceutical is focusing on cost control and enhancing its sales strategies to mitigate the risk of delisting [9][10]. - The company is working to expand its export business and improve its product quality while maintaining existing customer orders [9]. - Despite these efforts, doubts remain about the effectiveness of these strategies given the ongoing pressures in the pharmaceutical industry and limited resources for research and market expansion [11].

金融界消息 截至2025年7月31日收盘，*ST双成（002693）报收于8.3元，上涨4.4%，换手率7.15%，成 交量29.40万手，成交金额2.44亿元。 资金流向方面，今日主力资金净流入3752.16万元，占比成交额15.39%。其中，超大单净流入1533.26万 元、占成交额6.29%，大单净流入2218.90万元、占成交额9.1%，中单净流出流出1622.48万元、占成交 额6.66%，小单净流出2129.69万元、占成交额8.74%。 天眼查商业履历信息显示，海南双成药业股份有限公司，成立于2000年，位于海口市，是一家以从事医 药制造业为主的企业。企业注册资本41468.975万人民币，实缴资本41468.975万人民币。公司法定代表 人为王成栋。 通过天眼查大数据分析，海南双成药业股份有限公司共对外投资了2家企业，参与招投标项目141次，知 识产权方面有商标信息28条，专利信息15条，此外企业还拥有行政许可301个。 来源：金融界 *ST双成最新一期业绩显示，截至2025中报，公司营业总收入8412.21万元、同比减少11.35%，归属净利 润1846.66万元，同比减少8.97%，扣非净 ...

Summary of Key Points Core Viewpoint - In July 2023, 19 companies released their semi-annual reports for 2025, with 12 companies reporting year-on-year profit growth and 7 reporting declines. Notably, 10 companies experienced simultaneous growth in both net profit and revenue, while 6 companies saw declines in both metrics. The most significant profit increase was reported by Dong'an Power, with a growth rate of 157.75% [1]. Group 1: Company Performance - Dong'an Power reported earnings per share of 0.0167, with a net profit of 3.92 million and a year-on-year increase of 157.75%. Revenue reached 247.91 million, up 25.72% [1]. - Ding Tong Technology achieved an earnings per share of 0.8300, net profit of 115.40 million, and a year-on-year increase of 134.06%. Revenue was 78.46 million, up 73.51% [1]. - Zhiwei Intelligence reported earnings per share of 0.4100, net profit of 10.17 million, with an 80.08% year-on-year increase. Revenue was 194.69 million, up 15.29% [1]. - Huijia Times reported earnings per share of 0.1425, net profit of 6.70 million, with a year-on-year increase of 62.64%. Revenue was 127.12 million, up 2.29% [1]. - Ningde Times reported earnings per share of 6.9200, net profit of 3,048.51 million, with a year-on-year increase of 33.33%. Revenue was 17,888.63 million, up 7.27% [1]. Group 2: Declining Performance - Anada reported a loss per share of -0.1222, with a net loss of 2.63 million, reflecting a year-on-year decline of 158.08%. Revenue was 87.59 million, down 10.51% [2]. - Weitong Communication reported earnings per share of 0.0675, with a net profit of 3.10 million, down 68.57% year-on-year. Revenue was 35.99 million, down 24.62% [2]. - New Tian Pharmaceutical reported earnings per share of 0.0236, with a net profit of 576.61 thousand, down 80.99% year-on-year. Revenue was 35.83 million, down 18.88% [2].

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical industry and the need for strategic adjustments to improve performance [2][4]. Financial Performance - Revenue for the first half of 2025 was CNY 84,122,087.60, a decrease of 11.35% compared to CNY 94,892,601.28 in the same period last year [2][4]. - The net profit attributable to shareholders was a loss of CNY 18,466,557.74, compared to a loss of CNY 16,946,164.02 in the previous year, reflecting an 8.97% increase in losses [2][4]. - The net cash flow from operating activities improved significantly, with a net outflow of CNY 1,590,356.53, a 93.23% improvement from a net outflow of CNY 23,505,112.58 in the previous year [2][4]. Industry Overview - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,227.52 billion in the first half of 2025, down 1.2% year-on-year, with total profits decreasing by 2.8% to CNY 176.69 billion [3]. - The company is recognized as a national high-tech enterprise, focusing on the research, production, and sales of peptide drugs, with several products approved for sale in international markets [3][4]. Business Operations - The company specializes in the development, production, and sales of injectable drugs, solid preparations, and active pharmaceutical ingredients, with a strong emphasis on chemical synthesis of peptide drugs [3][4]. - Key products include Thymosin Alpha 1, Somatostatin, and Bivalirudin, which have received various international approvals, including from the FDA and EMA [3][4]. Competitive Advantages - The company has established a comprehensive capability in generic drug research, registration, and patent management, with a robust pipeline of products aimed at international markets [4]. - The company has initiated the development of new peptide synthesis technologies to reduce environmental impact and production costs, enhancing its competitive edge [4].